In 2019, the FDA expanded the indications for T-DM1 to include adjuvant treatment for early HER2-positive breast cancer patients who had residual invasive disease in the breast or lymph nodes after neoadjuvant treatment with a taxane and trastuzumab-based regimen, as investigated in the KATHERINE trial. This evidence concerns the gene ERBB2 and breast carcinoma.